Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies

L Succony, DM Rassl, AP Barker, FM McCaughan… - Cancer treatment …, 2021 - Elsevier
Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

DR Caswell, P Gui, MK Mayekar, EK Law, O Pich… - Nature Genetics, 2024 - nature.com
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …

AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer

PA Jänne, JCH Yang, DW Kim… - … England Journal of …, 2015 - Mass Medical Soc
Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …

Non-small-cell lung cancers: a heterogeneous set of diseases

Z Chen, CM Fillmore, PS Hammerman, CF Kim… - Nature Reviews …, 2014 - nature.com
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

CL Arteaga, JA Engelman - Cancer cell, 2014 - cell.com
ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

EA Akbay, S Koyama, J Carretero, A Altabef… - Cancer discovery, 2013 - AACR
The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that
immune escape mechanisms contribute to lung tumor pathogenesis. We identified a …

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …

R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

[HTML][HTML] A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi… - Cell, 2010 - cell.com
Accumulating evidence implicates heterogeneity within cancer cell populations in the
response to stressful exposures, including drug treatments. While modeling the acute …

Screening for epidermal growth factor receptor mutations in lung cancer

R Rosell, T Moran, C Queralt, R Porta… - … England Journal of …, 2009 - Mass Medical Soc
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …